Indianapolis Business Journal

Eli Lilly and Co.’s antibody treatment for COVID-19 is back on the market, ending a two-month suspension by the FDA. John Russell reports that the drug cocktail is back in regulators’ good graces after proving effective against the delta variant. Also in this week’s issue, Kurt Christian reports that RE/MAX is suing one of its local franchisees for allegedly instructing his employees to join a national competitor so that he could later follow them and collect a recruitment bonus. And Mickey Shuey explains how city officials are trying to address the futures of the huge municipal buildings that largely will be vacated as agencies move to the new Community Justice Campus.